Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) Sees Large Growth in Short Interest

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) saw a significant growth in short interest in the month of April. As of April 30th, there was short interest totaling 75,707 shares, a growth of ∞ from the April 15th total of 0 shares. Based on an average daily volume of 578,100 shares, the days-to-cover ratio is currently 0.1 days.

Lakewood-Amedex Biotherapeutics Stock Down 36.7%

Shares of Lakewood-Amedex Biotherapeutics stock traded down $0.55 during midday trading on Monday, hitting $0.95. 37,660,959 shares of the company traded hands, compared to its average volume of 5,513,425. Lakewood-Amedex Biotherapeutics has a 12 month low of $0.92 and a 12 month high of $9.82.

Analyst Ratings Changes

Separately, Wall Street Zen raised Lakewood-Amedex Biotherapeutics to a “hold” rating in a report on Saturday, May 2nd.

About Lakewood-Amedex Biotherapeutics

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.